Ipilimumab 3 mg/kg vs 10 mg/kg in Metastatic Melanoma
Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses a trial comparing two doses of ipilimumab for patients with metastatic melanoma.
Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses a trial comparing two dosages of ipilimumab for patients with metastatic melanoma.
The trial, which compared 3 mg/kg and 10 mg/kg of ipilimumab, was completed quickly because of the high rate of patient accrual in Europe, Sosman says. At the time of the trial, ipilimumab had been approved in the U.S. but not in Europe.
Clinical Pearls
Sosman expects the results from this trial to reveal a sense of the toxicity difference between two doses of ipilimumab.
- A trial comparing 3 mg/kg of ipilimumab and 10 mg/kg of ipilimumab in patients with metastatic melanoma has been completed
- Patient accrual was completed quickly
- Data will reveal a sense of the toxicity difference between two doses of ipilimumab
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
